Home
BLEIBEN SIE UPTODATE
Registrieren Sie sich für unseren monatlichen Newsletter.
Ihre Adresse wird nicht an Dritte weitergegeben.
Zu unseren Datenschutz-Bestimmungen.

   

Newsbericht November 2016

Tragen Sie Ihre News ein
Multidrug-resistant TB another facet to migration in Europe
Infection with MDR-TB is higher among migrants 30th November 2016, London: Multidrug-resistant tuberculosis (MDR-TB) is widespread globally with almost half a million cases documented in 2014. Although rare in European countries, the risks posed by the current migrant crisis makes MDR-TB an important and urgent public health priority. A study just published in Clinical Microbiology and Infection documents that the rate of infection with MDR-TB is higher among migrants than in the general population, particularly in those born outside Europe and in those forced to leave their home country as asylum seekers and refugees.[i] The data reviewed by Hargreaves et al. shows that 100% of the MDR-TB cases diagnosed in Austria, The Netherlands and Norway occurred in migrants to those countries. A high proportion of MDR-TB cases were also apparent in migrants to other European states – 90% in the UK, 89% in France, 87% in Italy and 94% in Germany. Migrants are at higher risk of contracting MDR-TB both in their country
30.11.2016  |  484x  |  Kurzbericht
BD MAX™ Vaginal Panel Receives FDA Market Authorization
Receives FDA Market Authorization to Detect Most Common Causes of Vaginal Infections BD MAX™ Vaginal Panel Receives FDA Market Authorization to Detect Most Common Causes of Vaginal Infections Expands Reproductive and Sexually Transmitted Infections Portfolio with First Test Using Microbiome-based Algorithm for Bacterial Vaginosis Detection Franklin lakes, N.J., Oct. 31, 2016 – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced U.S. Food and Drug Administration (FDA) market authorization for a first-of-its-kind molecular test to detect the most common causes for vaginitis. Laboratories and clinicians will now have the ability to use a single test to detect microorganisms responsible for Bacterial Vaginosis (BV), Trichomoniasis (TV) and Vulvovaginal Candidiasis (VVC), also known as a yeast infection, which are the most common infectious causes of vaginitis.1,2,3 The new in vitro diagnostic (IVD) assay is the first multiplex, real-time polymerase chain reaction (PCR) assay authorized by
28.11.2016  |  424x  |  Kurzbericht
Successful AAALAC accreditation for Envigo facilities in Barcelona, Spain
Successful AAALAC accreditation for Envigo facilities
in Barcelona, Spain 22 November 2016: Princeton, NJ — Envigo has announced that its contract research facilities in Barcelona, Spain have been granted full accreditation by the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC) International Council. In a letter to Envigo, AAALAC notified the company that it had met all the conditions required for full accreditation and commended Envigo employees “for providing and maintaining a high quality program of laboratory animal care and use.” This is the fourth accreditation of Envigo sites in 2016, demonstrating ongoing progress towards the company’s goal to have all of its contract research and research models sites accredited by AAALAC. Recent enhancements of Envigo’s Barcelona facilities in Santiga and Castellar were noted by AAALAC. As part of an investment in these sites, Envigo recently built a new surgery room, refurbished several key areas used for contract research and animal boarding, as well as installed
23.11.2016  |  431x  |  Kurzbericht  | 
French GPs vaccinate their children and patients differently
More than half of general practitioners (GPs) recommend vaccination for their patients that differ from their practices for their own children, according to a survey in France, which was recently published in the journal Clinical Microbiology and Infection. The physicians’ attitudes varied for different reasons, like the confidence they have on the benefits and the safety of individual vaccines. In France, GPs are the cornerstone of the vaccination programme as there is no school-based vaccination scheme. Official public health policy makes vaccinations against tetanus, diphtheria and polio mandatory while it recommends others including measles-mumps-rubella vaccine (MMR), hepatitis B vaccine (HepB), human papillomavirus vaccine (HPV) and the vaccines against meningococcus C (MenC). Researchers led by Pierre Verger and Céline Pulcini, from the Aix Marseille and Lorraine Universities, France surveyed 1,038 GPs who had at least one child aged between two and 25
22.11.2016  |  438x  |  Kurzbericht
Successful AAALAC accreditation for Envigo Barcelona
Envigo facilities in Barcelona 22 November 2016: Princeton, NJ — Envigo has announced that its contract research facilities in Barcelona, Spain have been granted full accreditation by the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC) International Council. In a letter to Envigo, AAALAC notified the company that it had met all the conditions required for full accreditation and commended Envigo employees “for providing and maintaining a high quality program of laboratory animal care and use.” This is the fourth accreditation of Envigo sites in 2016, demonstrating ongoing progress towards the company’s goal to have all of its contract research and research models sites accredited by AAALAC. Recent enhancements of Envigo’s Barcelona facilities in Santiga and Castellar were noted by AAALAC. As part of an investment in these sites, Envigo recently built a new surgery room, refurbished several key areas used for contract research and animal boarding, as well as installed
22.11.2016  |  502x  |  Kurzbericht
Plasticell’s CombiCult® technology platform
expansion of stem cells in umbilical cord blood 22 November 2016, Stevenage UK: Plasticell, the leader in high through-put technology to develop stem cell therapies in regenerative medicine, has announced the publication of peer-reviewed scientific research in the journal Stem Cells and Development, which demonstrates how the company’s award-winning platform technology can be used to discover novel cell culture protocols that expand specific populations of therapeutic stem cells present in cord blood. Hematopoietic stem cell (HSC) transplantation - the most successful and common stem cell therapy to date - is used to treat a wide variety of haematological disorders. Banked cord blood (CB) has several advantages over alternative sources of HSCs, as it is readily available, tested and banked ahead of use, contains more immature HSC and is associated with fewer cases of graft versus host disease. However, each CB unit contains too few stem cells to treat older children and adult patients - therefore methods of amplifying
22.11.2016  |  501x  |  Kurzbericht
European Antibiotic Awareness Day:
ESCMID experts promote prudent use of antibiotics to fight resistance 18 November 2016, Basel: Experts at the European Society of Clinical Microbiology and Infectious Disease (ESCMID) are joining colleagues across the globe this week to promote prudent use of antibiotics. They show their support for the European Antibiotic Awareness Day (EAAD) on 18 November, which was inaugurated in 2006 to raise awareness of antimicrobial resistance. EAAD forms part of World Antibiotic Awareness week from 14 – 20 November, which reflects the fact that the war against antimicrobial resistance must be a global effort. Some of the society’s activities throughout this week and since its foundation more than 30 years ago are highlighted on its dedicated Fighting Resistance webpage. Prof. Jesús Rodríguez-Baño, Escmid president-elect and Secretary General: “Antimicrobial resistance is a global threat that has been at the core of ESCMID’s activities. Our experts have been committed to developing hands-on solutions by supporting and promoting research and
18.11.2016  |  436x  |  Kurzbericht
LLG Single Channel microliter pipettes LLG-proMLP New in Boom’s LLG Labware product range
LLG Single Channel microliter pipettes LLG-proMLP
New in Boom’s LLG Labware product range he new LLG-proMLP single channel microliter pipettes combine high accuracy and reliability with ergonomic and extremely low force pipetting relieving stress from your hand and thumb. This high precision instrument has been built to maintain accuracy for many years making it the ideal choice for all scientific work requiring exact and reproducible pipetting. The LLG-proMLP pipettes are equipped with an adjustable eject button allowing right and left handed users to set the button* according to their preferences. The built in volume locking mechanism and competitive pricing complete these high quality precision pipettes. Available volume ranges from 0.1 µl to 10 ml. - High accuracy, reliability and reproducibility - Extremely light weight while the robustness still remains - Perfect ergonomics for highest comfort - Colour-coded push-button for quick operation - Extremely low pipetting forces - Built-in volume locking for error-free results - Tip ejector
10.11.2016  |  672x  |  Produktnews  | 
GC/LC/MS-Workstations
GC/LC/MS-Workstations
KRSS MS,GC and LC Workstations are ergonomically designed to make it easier to use your LC/GC/MS by providing a number of unique features and benefits. We are often asked how our benches are different to other products on the market, below we have highlighted just a few of our unique features... Designed and made in the UK Designed and manufactured at our facilities in Cheshire we use a combination of the latest techniques and technology to create products that are built to last. All round access Magnetic access panels allows for easy access to the pump and control PC. Unique slide out pump tray A sliding pump tray allows full access to the pumps, filters and connectors. Maintain optimum pump temperature Automatic thermal fans adjust speed to the ambient temperature. Designed to keep power consumption and noise levels at minimum and deliver high performance cooling when required. Fire resistant not fire retardant Our high density ?’0’? fire rated
09.11.2016  |  1893x  |  Produktbeschreibung  | 
calScreener™ use in anti microbial suspectibililty testing
Symcel, TiKa Diagnostics and St. George’s University of London form partnership Symcel: 08 November 2016: Symcel, the company behind the revolutionary cell-based assay tool for real-time cellular bioenergetic measurements, calScreener™, has partnered with TiKa Diagnostics and St. George’s University of London, for the use of its microcalorimetry technology in testing mycobacteria and for antimicrobial peptide (AMP) studies. The rapid detection of antimicrobial resistance is now crucial to maximize efforts in controlling the prevalence and spread of drug resistant Mycobacterium tuberculosis (Mtb). Moreover, the development of novel agents, such as AMPs, able to combat superbugs and interfere with biofilm formation, has become a key necessity. The project between Symcel and TiKa Diagnostics, a spin-out from St. George’s University of London, has the potential to enable rapid Mtb culture confirmation, reducing detection time to just two to six days rather than the average 12 to 14 day timespan required using conventional culture testing techniques.
08.11.2016  |  407x  |  Kurzbericht
Envigo launches hepatotoxicity testing
This comes as part of wider integrated drug development de-risking program Princeton, NJ, November 7, 2016. Envigo announces the launch of an integrated program of in vitro technologies that help predict the likelihood of compounds causing drug induced livery injury (DILI) – one of the major causes of drugs being withdrawn from the market. Since 1980, over 30 drugs have been withdrawn because of hepatotoxicity with many others having severe restrictions placed upon their use. As a consequence - and to help minimise any risks to patients taking their medicines - the pharma industry is concerned not to progress compounds that show any potential DILI liability. The new Envigo DILI Assessment program can help identify whether a drug exhibits possible risk factors associated with drug induced liver injury. The program can be run in full, using all of its tests, or can be conducted using single assays as required. “Envigo’s battery of in vitro tests, typically using human cells, enables our customers to determine if a compound carries a DILI
07.11.2016  |  433x  |  Kurzbericht
Hycult Biotech Introduces Diagnostic Calprotectin ELISA
Hycult Biotech has introduced a new diagnostic ELISA kit which can be used for the quantification of fecal Calprotectin. An advantage of this ELISA kit is that it is a one-step kit with a working time of only 90 minutes. Furthermore, this product has been clinically validated and optimized for use in automation. More information can be found on our website.
04.11.2016  |  473x  |  Kurzbericht
PANalytical launches, a benchtop X-ray powder diffractometer A surprisingly intuitive companion for everyday X-ray diffraction
PANalytical launches, a benchtop X-ray powder diffractometer
A surprisingly intuitive companion for everyday X-ray diffraction 1 November 2016, Almelo, the Netherlands. PANalytical, world’s leading supplier of analytical X-ray instrumentation and software, announces the launch of Aeris, their new X-ray powder diffraction (XRD) benchtop instrument. Ease of use and maximum benefits for the user have been the key aspects of this newly developed system, which provides fast and precise phase information of the materials analyzed. Aeris is accessible for everyone – its built-in touch screen with the intuitive interface directly displays all results. At the same time Aeris is designed for low cost of ownership – it only requires a single-phase power outlet and neither needs cooling water nor compressed air. Nevertheless, as the instrument incorporates many technologies proven on PANalytical’s high-end systems, its performance is exceeding typical benchtop X-ray diffractometer performance. Data quality and speed of data acquisition have so far only been observed on full-power systems. Additionally,
04.11.2016  |  483x  |  Kurzbericht  | 
Plasticell completes £1.32 million financing
Financing to go to advancing therapeutic projects Stevenage, UK, 4 November 2016 Plasticell, the biotechnology company specialising in cell and gene therapy research, announces the completion of a two-part equity financing round, raising a total of £1.32 million from its shareholders and new investors. The investment will provide capital to progress the company’s therapeutic programmes, including the expansion of hematopoietic stem cells and in vitro manufacturing of blood products such as platelets, red blood cells and cancer immunotherapies. Plasticell specialises in using massively parallel screening technologies to optimise high value cell therapies derived from stem cells. Its award-winning platform technology, CombiCult®, can be applied to any cell culture process, including biopharmaceutical production, as well as cell and gene therapy manufacturing. Plasticell’s lead therapeutic programme is in the expansion of hematopoietic stem cells derived from bone marrow and cord blood. Last year the company
04.11.2016  |  415x  |  Kurzbericht
Introduction of the new GC-TOFMS Solution LECO Pegasus® Benchtop (BT)
Introduction of the new GC-TOFMS Solution
LECO Pegasus® Benchtop (BT) Today’s laboratories are being asked to do more everyday—more samples run, more data acquired, more chemical information processed, and more results achieved—all in less time, for less money. With LECO’s Pegasus BT users will get all of the data they need from a single sample run, without the need for additional laboratory support. Unique and powerful software and hardware features simplify quantitation while also identifying more components with increased sensitivity. A StayClean™ ion source virtually eliminates the need for source cleaning, while a convenient benchtop package saves valuable space in the laboratory. The Pegasus BT will give users more uptime, improved chemical data, and an increase in overall productivity and efficiency. Features - Industry-leading sensitivity helps you find and quantify an unlimited number of analytes, while working with proprietary deconvolution algorithms to yield clean, high-quality spectra. - Complete historical record
03.11.2016  |  720x  |  Produktnews  | 
Farewell Henk Valster Hettich Benelux Almost nine years director
Farewell Henk Valster Hettich Benelux
Almost nine years director What started out as a short-term interim job ended up in being a director for almost nine years. Henk Valster has been at the basis of many developments within Hettich Benelux. On November 25, he leaves the company. In the next (November) issue of LABInsights he shares his views on the industry and it’s future developments.
03.11.2016  |  583x  |  Kurzbericht  | 
Airport door handles, helping spread AMR bacteria?
Airports are international travel hubs visited by large numbers of people. London Heathrow, for example, has an average of 205,400 travellers every day and saw 75 million people arriving and departing from all over the world in 2015. A study just published in the journal Clinical Microbiology and Infection suggest that international travellers can acquire antimicrobial-resistant bacteria and may spread these bacteria in their home countries after returning from abroad It seems plausible that drug-resistant bacteria from an individual traveller could be transferred to inanimate surfaces and then picked up by others but studying and quantifying this is fraught with problems. A group of researchers led by Frieder Schaumburg from the University Hospital Münster, Germany, came with an ingenious approach. Every time a member of their research group travelled internationally and passed through an airport, they swabbed the surface of an internal airport toilet door,
02.11.2016  |  428x  |  Kurzbericht
ARCHIV
NOV
2016
OKT
2016
SEP
2016
AUG
2016
JUL
2016
JUN
2016
MAI
2016
APR
2016
MAR
2016
FEB
2016
JAN
2016
DEZ
2015
MAXUS MEDIA
LABinsights.net LABinsights.de LABinsights.nl
Erhalten Sie unseren Newsletter
Newsletter Archiv
SERVICE UND KONTAKT flag